PD-1 inhibitior

DRUG2 trials

Sponsors

Mabwell (Shanghai) Bioscience Co., Ltd., Tianjin Medical University Second Hospital

Conditions

Kidney-sparingNab-paclitaxelNeoadjuvant TherapyPD-1 InhibitorTislelizumabTriple-Negative Breast CancerUreteral Cancer

Phase 2

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

RecruitingNCT06492005

Mabwell (Shanghai) Bioscience Co., Ltd.Triple-Negative Breast Cancer

Start: 2024-07-26End: 2027-07-31Target: 160Updated: 2025-01-10

Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer

RecruitingNCT07125547

Tianjin Medical University Second HospitalKidney-sparing, Nab-paclitaxel, Neoadjuvant Therapy +3

Start: 2025-07-05End: 2030-12-30Target: 35Updated: 2025-08-15